Public Profile

Ziska Pharmaceuticals Ltd

Ziska Pharmaceuticals Ltd., a prominent player in the pharmaceutical industry, is headquartered in Bangladesh (BD) and operates extensively across South Asia and beyond. Founded in 1992, the company has established itself as a leader in the development and manufacturing of high-quality generic medicines, particularly in the fields of anti-infectives, cardiovascular, and central nervous system treatments. Ziska Pharmaceuticals is renowned for its commitment to innovation and quality, offering a diverse portfolio of products that cater to various therapeutic areas. The company’s state-of-the-art manufacturing facilities adhere to international standards, ensuring the delivery of safe and effective medications. With a strong market presence and a reputation for excellence, Ziska Pharmaceuticals continues to make significant strides in improving healthcare outcomes in the regions it serves.

DitchCarbon Score

How does Ziska Pharmaceuticals Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

10

Industry Average

Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

14

Industry Benchmark

Ziska Pharmaceuticals Ltd's score of 10 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.

44%

Ziska Pharmaceuticals Ltd's reported carbon emissions

Ziska Pharmaceuticals Ltd, headquartered in Bangladesh (BD), currently does not have available data on carbon emissions, as no specific emissions figures have been provided. Consequently, there are no reported Scope 1, 2, or 3 emissions figures to analyse. In the absence of concrete emissions data, it is important to note that Ziska Pharmaceuticals Ltd has not outlined any specific reduction targets or climate commitments. This lack of information suggests that the company may still be in the early stages of developing a comprehensive climate strategy. As the pharmaceutical industry increasingly prioritises sustainability, Ziska Pharmaceuticals Ltd may benefit from establishing clear climate commitments and reduction initiatives to align with industry standards and expectations.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Ziska Pharmaceuticals Ltd's primary industry is Chemicals nec, which is medium in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. Ziska Pharmaceuticals Ltd is headquartered in BD, which has a rank of medium, indicating medium grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Ziska Pharmaceuticals Ltd is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
Carbon Disclosure Project
The Climate Pledge
UN Global Compact

Similar Organizations

Acme

US
Other business services (74)
Updated 5 days ago

Renata PLC

BD
Chemicals nec
Updated 5 days ago

Square Pharmaceuticals

BD
Medical, precision and optical instruments, watches and clocks (33)
Updated 5 days ago

Central Pharmaceuticals Ltd.

BD
Chemicals nec
Updated about 8 hours ago

Orion Pharma Limited

BD
Chemicals nec
Updated 5 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers